Publications by authors named "Iskra Pusic"

41Publications

Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial.

Biol Blood Marrow Transplant 2020 Sep 25;26(9):1612-1619. Epub 2020 May 25.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article and Find Full Text PDF
September 2020

Ruxolitinib for steroid-refractory acute graft-versus-host disease.

Transpl Int 2020 Feb 13;33(2):244-246. Epub 2019 Dec 13.

Department of Medicine, Division of Oncology, Washington University School of Medicine in Saint Louis, Saint Louis, MO, USA.

View Article and Find Full Text PDF
February 2020

The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation.

Am J Transplant 2020 02 11;20(2):589-592. Epub 2019 Sep 11.

Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.

View Article and Find Full Text PDF
February 2020

Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

Biol Blood Marrow Transplant 2019 10 28;25(10):2002-2007. Epub 2019 Jun 28.

Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio.

View Article and Find Full Text PDF
October 2019

Association of Leukemia Cutis With Survival in Acute Myeloid Leukemia.

JAMA Dermatol 2019 07;155(7):826-832

Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri.

View Article and Find Full Text PDF
July 2019

Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

N Engl J Med 2018 Sep;379(11):1028-1041

From the Department of Pathology and Immunology (E.J.D.), the Department of Medicine, Division of Oncology (M.A.J., C.A.M., N.E., J.S., K.E., J.R., S.E.H., K.B., L.D.W., M.J.C., I.P., J.S.W., G.L.U., D.C.L., J.F.D., P.W., T.J.L., M.J.W.), the McDonnell Genome Institute (G.S.C., C.A.M., H.A., R.S.F., C.C.F., M.O.), the Department of Medicine, Division of Hospital Medicine (R.S.), and Siteman Biostatistics Shared Resource, Siteman Cancer Center (K.T.), Washington University School of Medicine in St. Louis, St. Louis; and Massachusetts General Hospital Cancer Center, Boston (T.A.G.).

View Article and Find Full Text PDF
September 2018

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

N Engl J Med 2016 11;375(21):2023-2036

the Department of Internal Medicine, Division of Oncology (J.S.W., L.D.W., G.L.U., A.G., M.H.T., I.P., R.R., T.A.F., K.E.S.-G., R.V., S.T.O., C.N.A., A.F.C., M.A.S., M.A.J., S.E.H., K.L., M.R.J., M.J.W., P.W., D.C.L., J.F.D., T.J.L.), and the Division of Biostatistics (J.D.B.), and the Department of Pathology and Immunology (E.J.D., B.T., Y.-S.L.), Washington University School of Medicine, and McDonnell Genome Institute, Washington University in St. Louis (A.A.P., C.A.M., C.C.F., M.O., R.S.F., R.K.W., L.D.W., T.J.L.) - both in St. Louis; the Departments of Internal Medicine (A.H., N.K., M.J.S., W.S.) and Pharmacy (R.W.K.), University of Chicago, Chicago; and the Department of Internal Medicine (T.A.G.), Massachusetts General Hospital, Boston.

View Article and Find Full Text PDF
November 2016

Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?

Croat Med J 2016 Jun;57(3):239-46

Nadira Duraković, University Hospital Centre Zagreb, Dept of Internal Medicine, Division of Hematology, Kišpatićeva 12, 10000 Zagreb, Croatia,

View Article and Find Full Text PDF
June 2016

Biomarker Panel for Chronic Graft-Versus-Host Disease.

J Clin Oncol 2016 08 23;34(22):2583-90. Epub 2016 May 23.

Jeffrey Yu, Kushi Kushekhar, Mohammad Abu Zaid, and Sophie Paczesny, Indiana University School of Medicine, Indianapolis, IN; Barry E. Storer, Paul J. Martin, Mary E. Flowers, John A. Hansen, Stephanie J. Lee, Qing Zhang, Philip R. Gafken, and Yuko Ogata, Fred Hutchinson Cancer Research Center; Barry E. Storer, University of Washington School of Medicine, Seattle, WA; Mukta Arora, University of Minnesota, Minneapolis, MN; Corey Cutler, Dana-Farber Cancer Institute, Boston, MA; Madan Jagasia, Vanderbilt University, Nashville, TN; Joseph Pidala, H. Lee Moffitt Cancer Center, Tampa, FL; Betty K. Hamilton, Cleveland Clinic Foundation, Cleveland, OH; George L. Chen, Roswell Park Cancer Institute, Buffalo, NY; and Iskra Pusic, Washington University School of Medicine, St Louis, MO.

View Article and Find Full Text PDF
August 2016

Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.

Biol Blood Marrow Transplant 2016 06 14;22(6):1137-1141. Epub 2016 Mar 14.

Bone Marrow Transplantation and Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address:

View Article and Find Full Text PDF
June 2016

Economic evaluation of plerixafor for stem cell mobilization.

Am J Manag Care 2012 01;18(1):33-41

Center for Economic Evaluation in Medicine, Washington University School of Medicine, St. Louis, MO 63110-1093, USA.

View Article and Find Full Text PDF
January 2012

Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.

Curr Opin Hematol 2010 Jul;17(4):319-26

Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110, USA.

View Article and Find Full Text PDF
July 2010